Other Events ·
Verastem posts $24M Q3 revenue and updates pipeline with VS-7375 data
VSTMVerastem, Inc.
Verastem reported third-quarter net product revenue of $24 million for its AVMAPKI FAKZYNJA CO-PACK, noting steady demand and strong refill rates. The company furnished an updated corporate presentation highlighting clinical progress on its KRAS G12D inhibitor VS-7375, including confirmed responses in metastatic pancreatic ductal adenocarcinoma (mPDAC) and colorectal cancer (CRC). Upcoming milestones include a Phase 3 topline readout for RAMP 301 by mid-2027 and initial data from TARGET-D trials in early 2027. Verastem operates as an oncology company developing targeted therapies for RAS/MAPK pathway-driven cancers.